The universal demand to bring a COVID vaccine to market has expedited timelines in both preclinical and clinical research. While vaccine development efforts have been accelerated, traditional pathology evaluation struggles to change: Hematoxylin & Eosin-stained slides are shipped and viewed individually under a microscope – a process far too slow for the timelines the industry faces today.
Entos Pharmaceuticals (Entos), a company focused on genetic therapies, has developed Covigenix, a Fusogenix DNA vaccine against SARS-CoV-2, the virus that causes COVID-19. Reveal Biosciences teamed up with local collaborator Explora Biolabs in order to meet the expedited timelines for the preclinical study (a total of two weeks from necropsy to completed pathology review). Explora’s state of the art vivarium facilities and expert scientists led the in vivo work, while Reveal Biosciences transformed thousands of tissue samples into data-rich H&E whole slide images in just one week. Reveal Biosciences’ AI-powered imageDx QC™ tool was deployed over 3,500+ images in order to quickly assess and detect color variance, blurriness, stitching errors, artifacts, and tissue folds. Images that passed QC were made available in real-time to a DVM pathologist who remotely reviewed each image on the cloud-based platform in just a few days, utilizing built-in features such as high resolution zoom capabilities and creating and sharing annotations on specific regions of interest.
The seamless integration of imageDx™ with histopathology lab services demonstrates Reveal Biosciences’ cloud-based digital pathology platform as a vital part of accelerating ground-breaking research and providing powerful Pathology Intelligence™ insights, especially during a time where there is increased pressure on remote collaboration.
As a result of promising preclinical findings, Entos Pharmaceuticals was awarded funding to move forward with Phase I clinical trial of their COVID-19 DNA Vaccine. Entos is partnering with the Clinical Trials Research Center at the Canadian Center for Vaccinology in Nova Scotia to initiate phase I/II human clinical trials which will further evaluate the safety, tolerability, immunogenicity, and efficacy of Covigenix vaccine candidates.
About Reveal Biosciences
Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research and improve patient outcomes globally. Reveal’s imageDx™ SaaS pathology platform combines cutting edge artificial intelligence (AI) with traditional histopathology to transform tissue biology into actionable insights. imageDx™ provides AI data analytics and cloud-based whole slide image management to Life Sciences and Healthcare.
Reveal has its own fully automated laboratory and experienced scientists, providing histopathology, immunohistochemistry (IHC) and in situ hybridization (ISH) expertise for a wide range of pharmaceutical, biotech, academic, and government institutions. With a world class team of data and research scientists focused on addressing some of the biggest problems in healthcare, Reveal has developed a pipeline of AI-based digital assays for preclinical research, clinical trials, and decision support.
Reveal Biosciences is Headquartered in San Diego, California, and currently serves clients across the United States, United Kingdom, Europe, & the Asia Pacific.
Contact us at [email protected]